[{"id":"6a7737ea-7363-4409-b641-c11409e515ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181060","created_at":"2021-01-18T20:23:16.793Z","updated_at":"2025-02-25T12:37:29.255Z","phase":"Phase 3","brief_title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","source_id_and_acronym":"NCT04181060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-24"},{"id":"06aea852-4f4f-4fb7-987b-2400ee6b5c52","acronym":"ORBITAL","url":"https://clinicaltrials.gov/study/NCT04233021","created_at":"2021-01-18T20:35:29.375Z","updated_at":"2025-02-25T17:00:23.523Z","phase":"Phase 2","brief_title":"Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation","source_id_and_acronym":"NCT04233021 - ORBITAL","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 07/16/2020","start_date":" 07/16/2020","primary_txt":" Primary completion: 03/15/2023","primary_completion_date":" 03/15/2023","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2025-02-03"},{"id":"75b550a9-d016-442f-8549-62ab7dd6a2fd","acronym":"AZENT","url":"https://clinicaltrials.gov/study/NCT02841579","created_at":"2021-01-18T13:56:52.079Z","updated_at":"2025-02-25T15:07:10.729Z","phase":"Phase 2","brief_title":"Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M","source_id_and_acronym":"NCT02841579 - AZENT","lead_sponsor":"MedSIR","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/02/2016","start_date":" 09/02/2016","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 02/14/2020","study_completion_date":" 02/14/2020","last_update_posted":"2025-01-28"},{"id":"cadb8f0d-9482-4575-b4e2-ae2b496d1ae5","acronym":"U31402-A-U102","url":"https://clinicaltrials.gov/study/NCT03260491","created_at":"2021-01-17T17:11:50.865Z","updated_at":"2025-02-25T16:06:47.472Z","phase":"Phase 1","brief_title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03260491 - U31402-A-U102","lead_sponsor":"Daiichi Sankyo","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-11-22"},{"id":"229e5d3e-73c3-45a5-974b-b16c7567422e","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT05526755","created_at":"2022-09-02T17:00:16.764Z","updated_at":"2024-07-02T16:34:25.955Z","phase":"Phase 2","brief_title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","source_id_and_acronym":"NCT05526755 - TARGET","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 04/05/2029","primary_completion_date":" 04/05/2029","study_txt":" Completion: 04/05/2029","study_completion_date":" 04/05/2029","last_update_posted":"2024-06-14"},{"id":"66566ad0-5762-43b1-aaba-eb5e68316afa","acronym":"NCI-2019-05913","url":"https://clinicaltrials.gov/study/NCT04085315","created_at":"2021-01-18T19:59:58.628Z","updated_at":"2024-07-02T16:34:36.874Z","phase":"Phase 1","brief_title":"Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","source_id_and_acronym":"NCT04085315 - NCI-2019-05913","lead_sponsor":"Collin Blakely","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • alisertib (MLN8237)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/12/2019","start_date":" 11/12/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-10"},{"id":"839f620b-12d4-4a91-a1bc-669aefdc71c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496663","created_at":"2024-03-06T21:31:26.529Z","updated_at":"2024-07-02T16:34:58.872Z","phase":"Phase 1","brief_title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","source_id_and_acronym":"NCT02496663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"626349ae-5e92-4b7b-935d-204508ea15b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05546866","created_at":"2022-09-21T21:57:03.169Z","updated_at":"2024-07-02T16:35:00.447Z","phase":"Phase 2","brief_title":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","source_id_and_acronym":"NCT05546866","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/30/2029","primary_completion_date":" 06/30/2029","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-05-29"},{"id":"93f98008-2763-4eb8-b3d9-f6477ef24b99","acronym":"FURMO-002","url":"https://clinicaltrials.gov/study/NCT05364073","created_at":"2022-05-06T18:55:07.280Z","updated_at":"2024-07-02T16:35:02.618Z","phase":"Phase 1","brief_title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","source_id_and_acronym":"NCT05364073 - FURMO-002","lead_sponsor":"ArriVent BioPharma, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-20"},{"id":"7fda6a16-7aec-4560-a322-7d0985c54708","acronym":"EXCLAIM-2","url":"https://clinicaltrials.gov/study/NCT04129502","created_at":"2021-01-18T20:10:25.140Z","updated_at":"2024-07-02T16:35:03.030Z","phase":"Phase 3","brief_title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","source_id_and_acronym":"NCT04129502 - EXCLAIM-2","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-17"},{"id":"3aa290d8-6797-4cf2-a109-40a5ce47ce82","acronym":"NCI-2021-04325","url":"https://clinicaltrials.gov/study/NCT04940299","created_at":"2021-06-25T22:54:16.715Z","updated_at":"2024-07-02T16:35:03.655Z","phase":"Phase 2","brief_title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","source_id_and_acronym":"NCT04940299 - NCI-2021-04325","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra IV (tocilizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-15"},{"id":"63acc23b-8534-4603-8475-20ff97145f0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805631","created_at":"2023-04-10T14:03:05.133Z","updated_at":"2024-07-02T16:35:06.695Z","phase":"Phase 2","brief_title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","source_id_and_acronym":"NCT05805631","lead_sponsor":"Taipei Veterans General Hospital, Taiwan","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-01"},{"id":"f3aa5ebc-ff8a-48a1-8ade-20d99888b813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821933","created_at":"2023-04-20T14:03:56.574Z","updated_at":"2024-07-02T16:35:10.455Z","phase":"Phase 1/2","brief_title":"RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC","source_id_and_acronym":"NCT05821933","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-10"},{"id":"a2a285a5-555c-4e53-ba89-bdb5efd56b1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05401110","created_at":"2022-06-02T16:58:56.919Z","updated_at":"2024-07-02T16:35:12.049Z","phase":"Phase 1","brief_title":"Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05401110","lead_sponsor":"Karen Reckamp, MD, MS","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carotuximab IV (ENV-105)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/15/2023","start_date":" 09/15/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-04-02"},{"id":"d448b93f-39b9-4496-9d25-48f1c9adcfa3","acronym":"Balise","url":"https://clinicaltrials.gov/study/NCT01897480","created_at":"2021-01-18T08:31:57.339Z","updated_at":"2024-07-02T16:35:16.757Z","phase":"Phase 2","brief_title":"A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations","source_id_and_acronym":"NCT01897480 - Balise","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • emibetuzumab (LY2875358)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 08/28/2013","start_date":" 08/28/2013","primary_txt":" Primary completion: 03/14/2016","primary_completion_date":" 03/14/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-01"},{"id":"a57663a3-200f-4a64-8df5-537b7c4835d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04780568","created_at":"2023-12-11T17:16:35.473Z","updated_at":"2024-07-02T16:35:26.635Z","phase":"Phase 1","brief_title":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04780568","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" EGFR • NOTCH3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR • NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-11"},{"id":"24a9df1f-6dbc-4a16-8c54-13431c420129","acronym":"EXCLAIM","url":"https://clinicaltrials.gov/study/NCT02716116","created_at":"2021-01-17T17:11:37.814Z","updated_at":"2024-07-02T16:35:32.901Z","phase":"Phase 1/2","brief_title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02716116 - EXCLAIM","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 334","initiation":"Initiation: 06/16/2016","start_date":" 06/16/2016","primary_txt":" Primary completion: 03/28/2025","primary_completion_date":" 03/28/2025","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2023-10-18"},{"id":"4339bc3b-cd6e-40b5-bdb4-0ed50ce40904","acronym":"KCSG-LU15-09","url":"https://clinicaltrials.gov/study/NCT03434418","created_at":"2021-01-18T16:56:28.683Z","updated_at":"2024-07-02T16:35:33.271Z","phase":"Phase 2","brief_title":"A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations","source_id_and_acronym":"NCT03434418 - KCSG-LU15-09","lead_sponsor":"Duke University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/30/2018","start_date":" 06/30/2018","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 10/12/2022","study_completion_date":" 10/12/2022","last_update_posted":"2023-10-17"},{"id":"7eec8313-ce6d-47bc-92b7-e0a3b9ab9f7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468985","created_at":"2021-01-18T17:05:50.225Z","updated_at":"2024-07-02T16:35:33.350Z","phase":"Phase 2","brief_title":"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03468985","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative","tags":["EGFR • PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 05/09/2022","primary_completion_date":" 05/09/2022","study_txt":" Completion: 12/21/2022","study_completion_date":" 12/21/2022","last_update_posted":"2023-10-17"},{"id":"ff9136f8-fa30-4801-a841-e3d1bcb767ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05517083","created_at":"2022-08-26T13:58:51.157Z","updated_at":"2024-07-02T16:35:33.009Z","phase":"","brief_title":"Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer","source_id_and_acronym":"NCT05517083","lead_sponsor":"Pusan National University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR G719X • EGFR S768I"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-10-17"},{"id":"ea7b0831-aa27-4710-8ad0-16bc4a75633a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06067776","created_at":"2023-10-05T16:11:05.700Z","updated_at":"2024-07-02T16:35:34.583Z","phase":"Phase 1","brief_title":"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer","source_id_and_acronym":"NCT06067776","lead_sponsor":"Jonathan Riess","biomarkers":" HER-2 • BRAF • ALK • MET • RET","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation","tags":["HER-2 • BRAF • ALK • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-10-05"},{"id":"fe7a5d8e-4b89-442a-960a-83aeeffb3ee8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04790409","created_at":"2021-03-10T13:54:17.167Z","updated_at":"2024-07-02T16:35:37.014Z","phase":"Phase 2","brief_title":"Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations","source_id_and_acronym":"NCT04790409","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Tyvyt (sintilimab)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 09/13/2023","primary_completion_date":" 09/13/2023","study_txt":" Completion: 09/13/2023","study_completion_date":" 09/13/2023","last_update_posted":"2023-09-14"},{"id":"06bce804-bede-4084-9f43-37dffac91812","acronym":"CVL009-2001","url":"https://clinicaltrials.gov/study/NCT06029816","created_at":"2023-09-08T20:10:17.441Z","updated_at":"2024-07-02T16:35:37.650Z","phase":"Phase 2","brief_title":"Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations","source_id_and_acronym":"NCT06029816 - CVL009-2001","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-09-08"},{"id":"feaf3842-5e4a-453e-901d-d0761d859dda","acronym":"CULTRO","url":"https://clinicaltrials.gov/study/NCT05998993","created_at":"2023-08-21T16:09:21.153Z","updated_at":"2024-07-02T16:35:39.432Z","phase":"Phase 2","brief_title":"Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)","source_id_and_acronym":"NCT05998993 - CULTRO","lead_sponsor":"Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2023-08-21"}]